^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    temsirolimus

    i
    Other names: CCI 779, Cell cycle inhibitor-779, CCI-779, NSC-683864, NSC 683864, rapamycin analog CCI-779, CCI779, NSC683864
    Company:
    Generic mfg.
    Drug class:
    mTOR inhibitor
    Related drugs:
    3d
    In silico screening, synthesis, and biological evaluation of pyrazolopyrimidine-derived mTOR inhibitors for anticancer and senomorphic effects. (PubMed, Cancer Cell Int)
    Compound 5 demonstrates distinct biological effects compared to torkinib and represents a promising candidate for further development as an mTOR inhibitor targeting both cancer and senescent cells.
    Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    temsirolimus • torkinib (PP242)
    10d
    Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov)
    P3, N=236, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    AFP (Alpha-fetoprotein)
    |
    AFP elevation
    |
    cisplatin • doxorubicin hydrochloride • irinotecan • temsirolimus • vincristine • fluorouracil topical • dexrazoxane
    10d
    Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P2, N=349, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Ixempra (ixabepilone) • patupilone (EPO 906)
    15d
    Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov)
    P1, N=155, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Mar 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • temsirolimus
    16d
    Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (PubMed, JCO Precis Oncol)
    Temsirolimus demonstrated antitumor activity in patients with PIK3CA-mutated cancer within the UC and HP cohorts but not the BC or CRC cohorts.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    temsirolimus
    1m
    Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer. (PubMed, Cell Death Dis)
    Accordingly, the combination of ganetespib (an HSP90 inhibitor) and temsirolimus (a FDA approved-mTOR inhibitor) with cisplatin synergistically reduced colony formation and microtissues cell growth in vitro by increasing DNA-damage and apoptosis and in vivo enhancing mouse survival. Notably, all these data were confirmed also in Pt-resistant Non Small Cell Lung Cancer models. Collectively, our findings identify a promising new antitumor strategy for the treatment of Pt-resistance in cancer patients.
    Journal
    |
    RPS6 (Ribosomal Protein S6) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • HSF1 (Heat Shock Transcription Factor 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    cisplatin • temsirolimus • ganetespib (ADX-1612)
    1m
    A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours (clinicaltrials.gov)
    P2, N=137, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • NF1 (Neurofibromin 1)
    |
    EGFR mutation • PTEN mutation
    |
    sunitinib • temsirolimus
    2ms
    The potential of mitochondrial permeability transition-driven necrosis-related genes in prognostic evaluation of colorectal cancer patients. (PubMed, Front Oncol)
    Immunoassays revealed that high-risk patients had 9 elevated immune checkpoints, while low-risk patients were more susceptible to pazopanib and temsirolimus. Real-time PCR (RT-qPCR) confirmed low levels of CASP7, PRKCB, and ENDOG mRNA in CRC tissues, with no significant difference between LMNB2 and GZMB. These findings highlight 5 MPTDN-associated prognostic genes in CRC, providing insights for individualized treatment and prognosis.
    Journal
    |
    GZMB (Granzyme B) • CASP7 (Caspase 7) • PRKCB (Protein Kinase C Beta) • LMNB2 (Lamin B2)
    |
    pazopanib • temsirolimus
    2ms
    GSDME-mediated pyroptosis is essential for the chemotherapeutic effects achieved by combined treatment of temsirolimus and 5-fluorouracil in ovarian carcinoma cells. (PubMed, Am J Transl Res)
    GSDME is the principal executor of spontaneous pyroptosis in ovarian cancer tissues. In chemotherapy employing cell cycle-targeting agents or PI3K-AKT-mTOR pathway inhibitors (alone or in combination) is beneficial, and pyroptosis is an indispensable cell death mechanism. Reactive oxygen species act as a nodal regulator orchestrating pyroptosis, apoptosis, and ferroptosis.
    Journal
    |
    GSDME (Gasdermin E) • GSDMD (Gasdermin D)
    |
    5-fluorouracil • temsirolimus
    2ms
    Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    temsirolimus • Ixempra (ixabepilone) • patupilone (EPO 906)
    2ms
    TORERO: Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=45, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • temsirolimus
    2ms
    Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Rapa Therapeutics LLC | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    carboplatin • paclitaxel • temsirolimus • sirolimus • RAPA-201